{
    "nct_id": "NCT05274451",
    "official_title": "A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults With Relapsed and/or Refractory Solid-Tumor Malignancies",
    "inclusion_criteria": "* â‰¥ 18 years of age at time of informed consent\n* Confirmation of ROR1 expression from a pretreatment tumor sample\n* Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable\n* Platinum-resistant epithelial ovarian cancer/ fallopian tube cancer/ primary peritoneal cancer.\n* Endometrial cancer.\n* Measurable disease including a target lesion and an additional lesion for biopsy\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate organ and marrow function\n* Women of childbearing potential must have a negative pregnancy test at screening\n* All participants must agree to practice highly effective methods of contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with any adoptive T-cell therapy or other anti-ROR1 therapy\n* Prior solid organ transplantation\n* Active, untreated brain metastasis or leptomeningeal disease; however, stable, treated brain metastases are allowed\n* Untreated or active infection at the time of screening or leukapheresis\n* HIV-positive, HTLV-1-positive, active acute HAV, acute or chronic HBV or HCV, or active tuberculosis\n* Impaired cardiac function or clinically significant cardiac disease\n* Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures (once monthly or more frequent), or lymphangitis carcinomatosis\n* History of interstitial pneumonitis or pulmonary fibrosis.\n* Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis\n* Pregnant or lactating/nursing women",
    "miscellaneous_criteria": "I"
}